* Becoming the first to market, to try and salvage their reputation
* Using the vaccine as leverage toward the incoming sanctions for violating the Hong Kong treaty during UK handover, as well as the now-declared possible non-peaceful reunification of Taiwan
* monetary gain
* leverage against the US restricting/removing Chinese’s companies from the NASDAQ
I agree research should be open, but it’s hard to say to what degree, and how that might effect the economics of it. Whether we like it or not, capitalistic driven progress requires a reward, and one of the few reasons pharmaceutical companies will take the risk of finding a vaccine is the potential for increased reputation, and being first to market.
Without those incentives, it’s straightforward to not to take a massive monetary risk as others are all working on similar problems, thus the likelihood that your lab will be the first is slim.
Further, the crisis is a worldwide pandemic, but if the rate of natural immunity is as high as some predict, the efficacy of these vaccines may lead to less ‘sales’ than initially expected.
Oxford running out of people to test their vaccine on: https://news.cgtn.com/news/2020-05-25/COVID-19-disappearing-...
China report about Taiwan has “peaceful” removed: https://www.reuters.com/article/us-china-parliament-taiwan/c...
China breaking the handover treaty: https://www.theatlantic.com/international/archive/2020/05/ch...